Startups

Senior Director, DMPK Project Leader

Centessa Pharmaceuticals · Boston, MA · On-site

← All jobs
About Centessa Pharmaceuticals

Patient-Centric Mission. Asset-Centric Approach. We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders.... Backed by Foresite Capital.

About the role

Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • Ph.D. in Pharmaceutical Sciences, Pharmacology or a related field
  • Minimum of 10 years of industry experience in a biotech or pharmaceutical setting
  • Expert in DMPK sciences with knowledge of drug discovery and development processes
  • Strong analytical and problem-solving skills
  • Experience in DMPK project leadership
  • Previous work in the discovery and/or development of CNS drug candidates
More about this role

Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.

Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work ® in 2026.

Senior Director, DMPK Project Leader ensures delivery of all DMPK related activities working collaboratively as part of a cross-functional program team. These include nonclinical PK experiments, in vitro ADME, biotransformation studies, bioanalytical and toxicokinetic analysis. This role supports understanding pharmacokinetic, toxicokinetic, and ADME principles to enable progression of drug candidates across the portfolio. A qualified candidate will have previous...

Read the full posting on Centessa Pharmaceuticals's site ↗

DMPK

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.